Video

Matthew Galsky Gives an Overview of Bladder Cancer

Author(s):

Matthew Galsky, M.D.

Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.

Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.

Galsky gives an overview of each bladder cancer type, starting with non-muscle invasive bladder cancer, and talks about treatment options and likelihood of cure or recurrence.

Related Videos
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Related Content
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Cretostimogene shows best-in-class durability of response for BCG-unresponsive NMIBC with CIS: © pikovit - stock.adobe.com.
March 24th 2025

Cretostimogene Has Durable Response in BCG-Unresponsive Bladder Cancer

Ryan Scott
Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Jelmyto demonstrates long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months. © - stock.adobe.com
March 15th 2025

Jelmyto Maintains Effectiveness Over Time in Bladder Cancer Subtype

Spencer Feldman
Jelmyto demonstrated long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months.
Illustration of bladder cancer.
March 14th 2025

Blue Light Cystoscopy Reduces Recurrence in High-Risk Bladder Cancer

Ryan Scott
Blue light cystoscopy had a statistically significant reduction in risk of recurrence versus white light cystoscopy in high-risk bladder cancer.